Sherlock Biosciences, Cambridge, Mass, and binx health, Boston, have entered a strategic partnership to develop the world’s first rapid, point-of-care diagnostic test for covid-19 using CRISPR technology. The organizations will combine the binx io diagnostic platform with Sherlock CRISPR technology to create a test that is robust and simple to use.
This solution is designed to provide rapid and accurate results in a single patient visit across many diverse CLIA-waived settings, such as clinics, doctors’ offices, assisted living centers, pharmacies, and other easily accessible consumer venues, which will assist in broadening ways of managing potential resurgences of the pandemic.
“We are pleased to partner with Sherlock Biosciences to help bridge a gap in covdi-19 testing—the need for highly accurate point-of-care diagnostic testing in CLIA-waived and near-patient settings,” says Jeff Luber, chief executive officer of binx health. “Our proprietary platform will leverage Sherlock’s CRISPR-based assay combined with binx’s electrochemical detection for rapid viral detection of SARS-CoV-2 without the need for additional instrumentation. This union of technologies is designed to enable physicians, clinicians, and other healthcare workers on the front lines of the global covid-19 pandemic to make on-the-spot care decisions and to control and prevent further infections. We also have a unique alignment of vision with Sherlock for solutions that support ‘everywhere’ testing in near-patient retail and clinical settings.”
“This collaboration with binx health to advance our Sherlock diagnostic platform and offer an accurate, point-of-care test is the next critical step in combating the global covid-19 crisis,” says Rahul Dhanda, co-founder, president, and CEO of Sherlock Biosciences. “We are also excited to explore with binx how to utilize the io platform to bring accurate and affordable testing to hospitals, urgent care centers, and other healthcare facilities for a range of diagnostic tests beyond covid-19. We agree with the binx strategy that ‘everywhere care’ depends on highly accurate in-clinic and easy-to-use at-home solutions. Through both our Sherlock- and Inspectr-based platforms, we hope to serve as part of the solution to addressing the covd-19 pandemic by making accurate, affordable diagnostics available everywhere they are needed: in the lab, point-of-care locales, low-resource settings, and the home.”
For more information, visit Sherlock Biosciences and binx health.
